摘要
目的研究比较临床上使用尼洛替尼与伊马替尼治疗初诊慢性髓性白血病慢性期的疗效。方法回顾性选取初诊慢性髓性白血病慢性期患者60例,按给药方式分为对照组和观察组,各30例。观察组采用尼洛替尼治疗,1次/日,每次300 mg;对照组采用伊马替尼,1次/日,每次400 mg,连续治疗1年。比较观察组与对照组血液学缓解率、细胞遗传学缓解率、分子生物学缓解率以及不良反应发生率。结果给药治疗1年后,观察组血液学缓解率显著高于对照组(P<0.05);观察组细胞遗传学缓解率显著高于对照组(P<0.05);观察组分子生物学缓解率显著高于对照组(P<0.05)。给药治疗1年后,观察组不良反应发生率显著低于对照组(P<0.05)。结论尼洛替尼治疗初诊慢性髓性白血病慢性期疗效显著优于伊马替尼,且安全性较高。
Objective To study and compare the efficacy of nilotinib and imatinib in the treatment of newly diagnosed chronic myeloid leukemia(CML).Methods 60 patients with CML diagnosed in our hospital were divided into the control group(n=30)and the observation group(n=30).The observation group was treated with nilotinib,once a day,and the control group was treated with imatinib once a day,400mg for each time,continuously for 1 year.The hematological remission rate,cytogenetic remission rate,molecular biological remission rate and the incidence of adverse reactions were compared between the observation group and the control group.Results One year after treatment,the hematological remission rate in the observation group was significantly higher than that in the control group(P<0.05).One year after treatment,the cytogenetic remission rate in the observation group was significantly higher than that in the control group(P<0.05).After one year of treatment,the molecular biological remission rate in the observation group was significantly higher than that in the control group(P<0.05).After one year of treatment,the incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The efficacy of nilotinib in the treatment of newly diagnosed chronic myeloid leukemia is significantly better than that of imatinib,with higher safety.
作者
何玉卓
郭学军
林晓燕
朱鸿斌
HE Yuzhuo;GUO Xuejun;LIN Xiaoyan(Puyang Oilfield General Hospital,Puyang,457001)
出处
《实用癌症杂志》
2021年第7期1148-1151,共4页
The Practical Journal of Cancer
